Oracle acquires SiteWorks Solutions

Oracle has acquired the assets of SiteWorks Solutions, a producer of clinical trial management software.

Oracle has acquired the assets of SiteWorks Solutions, a producer of clinical trial management software.

The company will combine two products made by SiteWorks - SiteMinder and TrialMinder - with its Clinical application suite.

SiteMinder is used by hospitals and research institutions to plan, budget and manage their participation in clinical trials, while TrialMinder performs the same services for sponsoring pharmaceutical companies or contract research organisations. Both applications are web-based and run on the Oracle 9i database.

The Oracle Clinical suite is used by organisations conducting clinical trials to capture remote data easily, summarise medical terminology, track adverse events from all sources and respond to inquiries.

"Oracle is the standard in our industry. Adding our applications to their suite of products is a very compelling proposition for both the pharmaceutical industry and large academic medical centres," said SiteWorks Solutions chief executive officer Dee Anna Smith.

"We studied this market area long and hard, and we decided that what our customers needed told us to get a solution quickly rather than however long it would take to get a solution ourselves. We found SiteWorks was far and away the best company," said Keith Howells, vice-president of Oracle's pharmaceutical applications group.

Oracle hoped the acquisition will increase its profits. "Anything that helps our customers operate more efficiently, we believe they will pay accordingly for that capability," Howells added.

Katie Hamm writes for IDG News Service

Read more on Business applications

Start the conversation

Send me notifications when other members comment.

By submitting you agree to receive email from TechTarget and its partners. If you reside outside of the United States, you consent to having your personal data transferred to and processed in the United States. Privacy

Please create a username to comment.